Deloitte and Google Cloud plan expansion into healthcare and R&D

In Silico
The news just days after a separate from the Consumer Technology Association bringing together more than 30 industry members to develop standards and best practices for AI in healthcare, including Google, IBM, Fitbit and Advamed, among others. (Pixabay / Geralt)

Deloitte and Google’s cloud computing service are expanding their work deeper into the healthcare sector, with plans to provide life sciences companies with infrastructure for artificial intelligence and data analytics.

This includes technology aimed at expediting research and development, as well as improving operations. Specifically, Google Cloud will work with Deloitte to provide more companies with its Contact Center AI solution for customer assistance programs, alongside its clinical data warehousing and processing services for genomics and medical imaging.

“Together, we plan to transform operating models across these key sectors by harnessing the power of cloud technologies and the extensive industry-specific knowledge and experience of our practitioners,” Janet Foutty, chair and CEO of Deloitte Consulting, said in a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Amgen to consolidate its digital patient engagement systems under Deloitte banner

The collaboration also includes work in helping to modernize the retail and financial services sectors. The news was announced at Google Cloud’s annual developer conference in San Francisco, just days after a separate initiative was unveiled by the Consumer Technology Association to bring together more than 30 industry members to develop standards and best practices for incorporating AI in healthcare—including Google, IBM, Fitbit and Advamed, among others.

RELATED: WuXi NextCODE and Google Cloud partner to enhance global genomic access

Its tasks will include examining topics such as the trustworthiness, ethics and bias of AI-based algorithms, across the healthcare, fitness and wellness industries.

The initiative will be co-chaired by Pat Baird, regulatory head of global software standards at Philips, and Jerry Wilmink, chief business officer at CarePredict. The group plans to meet for the first time at CTA’s Technology & Standards forum in San Francisco this May.

RELATED: FDA lays out plans for a new review framework for AI and machine learning-based devices

“The rapid progress of AI presents great opportunities but a special challenge that needs urgent attention,” said Rene Quashie, CTA’s VP of policy, regulatory affairs and digital health.

“This unique working group represents a diverse set of stakeholders across the ecosystem, including clinicians, manufacturers, regulators, public policy and civil rights organizations,” Quashie said. “The work produced will provide an informed framework for the use of AI in the context of healthcare.”

Suggested Articles

GenapSys has unveiled its compact, high-throughput DNA sequencer, alongside a $90 million venture capital raise to help jump-start its launch.

LivaNova plans to restructure its heart valve operations, and will drop its investigational Caisson transcatheter mitral valve replacement altogether.

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.